| Twentyeight-Seven–Longwood Fund: investment, 201809 financing round Series A totalling $65m incl co-investor Longwood Fund |
2018-09-06 |
| Twentyeight-Seven–MPM Capital: investment, 201809 financing round Series A totalling $65m incl founding + co-lead investor MPM Capital |
2018-09-06 |
| Twentyeight-Seven–Novartis: investment, 201809 financing round Series A totalling $65m incl co-lead investor NVF |
2018-09-06 |
| Twentyeight-Seven–SEVERAL: investment, 201809 financing round Series A $65m co-led by founding investor MPM Capital + NVF |
2018-09-06 |
| Twentyeight-Seven–Temasek: investment, 201809 financing round Series A totalling $65m incl co-investor Vertex Ventures HC |
2018-09-06 |
| Creoptix–Waters: investment, 201809 investment by new investor Waters Corp |
2018-09-05 |
| Miracor–SEVERAL: investment, 201809 financing round Series D totalling €30m final closing led by Ming Capital (CN) |
2018-09-04 |
| Mologen–SEVERAL: investment, 201809 capital increase €8.2m with 1.73m new shares at €4.7/share to existing + new investors |
2018-09-03 |
| CHDI–Evotec: drug discovery services, 201808–2023 collab service extension CDHI funding up to 75 full-time scientists for Huntington’s disease drugs |
2018-08-30 |
| Lunaphore–SEVERAL: investment, 201808 financing round Series B CHF5.3m from existing + new investors |
2018-08-30 |
| Nebula Genomics–Heartbeat Labs: investment, 201808 seed financing round totalling $4.3m incl Heartbeat Labs |
2018-08-29 |
| Nebula Genomics–SEVERAL: investment, 201808 seed financing round $4.3m from ten leading tech + biotech VCs |
2018-08-29 |
| PhagoMed–Austria (govt): grant, 201808–2021 research project grant €3.5m from FFG |
2018-08-28 |
| PhagoMed–Austria (govt): investment, 201808 seed financing round totalling €1.55m incl €800k aws-Seedfinancing |
2018-08-28 |
| PhagoMed–OTHER: investment, 201808 seed financing round totalling €1.55m incl €750k from private investors |
2018-08-28 |
| PhagoMed–SEVERAL: investment, 201808 seed financing round €1.55m from private investors + aws |
2018-08-28 |
| Evotec–Centogene: drug discovery, 201808– collab ww strategic €na discovery + developm of treatments for rare genetic diseases |
2018-08-27 |
| Roche–Affimed: antibody cancer drug, 201808– collab $96m ufpront + $5b milestones + royalties using ROCK platform to develop ABs with Genentech |
2018-08-27 |
| Thermo Fisher–BioStrata: public relations, 201808 service existent by BioStrata |
2018-08-27 |
| Univ Wisconsin–Thermo Fisher: FAIMS technology, 201808 supply use of FAIMS device for shotgun proteomics by Joshua Coon |
2018-08-27 |
| Hain Lifescience–Bruker: investment, 201808– acquisition €na of 80% majority interest with option to acquire rest in 2012 ANNOUNCED |
2018-08-24 |
| c-LEcta–Capricorn Venture Partners: investment, 201808 financing round incl new + lead investor Capricorn investing via CSCF NV + Quest for Growth |
2018-08-23 |
| c-LEcta–SEVERAL: investment, 201808 financing round €na with new investors Capricorn Venture Partners + bm|t |
2018-08-23 |
| c-LEcta–Thuringia (govt): investment, 201808 financing round incl new + co-investor bm|t via MFT Mittelstands-Fonds Thüringen |
2018-08-23 |
| Novaremed–SEVERAL: investment, 201804 financing round CHF4.44m to support phase 2b study of NRD.E1 in DNP |
2018-08-23 |
| Novaremed–SEVERAL: investment, 201808 financing round CHF6m to support phase 2b study of NRD.E1 in DNP |
2018-08-23 |
| Merck (DE)–GlucoMe: digital health, 201808– collab digital diabetes management project in Vietnam |
2018-08-22 |
| Novo Group–Evotec: drug discovery services, 201808– collab €na strategic alliance r+d small molecule drugs for diabetes + obesity Novo Nordisk |
2018-08-22 |
| SolasCure–BRAIN: investment, 201808 financing round Series A with participation of BRAIN at spin-off of SolasCure from BRAIN |
2018-08-22 |
| SolasCure–BRAIN: wound care product, 201808– license IP for Aurase enzyme + supply of enzymatic active ingredient by BRAIN to SolasCure |
2018-08-22 |
| SolasCure–SEVERAL: investment, 201808 financing round Series A with participation of BRAIN |
2018-08-22 |
| NuGen–Tecan: investment, 201808 acquisition $54.5m in cash by Tecan |
2018-08-16 |
| Oncologie–Mologen: lefitolimod, 201808–201811 term sheet for acquisition of ww rights to lefitolimod by Oncologie TERMINATED 11/18 |
2018-08-15 |
| Bayer–Haplogen: antiviral agents, 201808– collab €na developm candidates for pulmonary diseases incl COPD |
2018-08-14 |
| Artios Pharma–AbbVie: investment, 201808 financing round Series B totalling $84m incl existing + co-investor AbbVie Ventures |
2018-08-10 |
| Artios Pharma–Andera Partners: investment, 201808 financing round Series B totalling $84m (£65m) incl new + lead investors Andera Partners + LSP |
2018-08-10 |
| Artios Pharma–Arix Bioscience: investment, 201808 financing round Series B totalling $84m incl existing + co-investor Arix Bioscience |
2018-08-10 |
| Artios Pharma–IP Group: investment, 201808 financing round Series B totalling $84m incl existing + co-investor IP Group |
2018-08-10 |
| Artios Pharma–Life Sciences Partners: investment, 201808 financing round Series B totalling $84m incl new + lead investors Andera Partners + LSP |
2018-08-10 |
| Artios Pharma–Merck (DE): investment, 201808 financing round Series B totalling $84m incl existing + co-investor M Ventures |
2018-08-10 |
| Artios Pharma–Novartis: investment, 201808 financing round Series B totalling $84m incl new + co-investor Novartis Venture Fund |
2018-08-10 |
| Artios Pharma–Pfizer: investment, 201808 financing round Series B totalling $84m incl new + co-investor Pfizer Ventures |
2018-08-10 |
| Artios Pharma–SEVERAL: investment, 201808 financing round Series B $84m (£65m) led by new investors Andera Partners + LSP |
2018-08-10 |
| Artios Pharma–SV Health Investors: investment, 201808 financing round Series B totalling $84m incl existing + co-investor SV |
2018-08-10 |
| Akouos–Novartis: investment, 201808 financing round Series A totalling $50m incl new co-investor Novartis Venture Fund |
2018-08-07 |
| Akouos–SEVERAL: investment, 201808 financing round Series A $50m co-led by existing investors 5AM Ventures + NEA |
2018-08-07 |
| United Kingdom (govt)–Bruker: NMR technology, 201808 supply £20m NMR technology to 8 UK universities funded by EPSRC + BBSRC + MRC +NERC |
2018-08-06 |
| Univ Birmingham–Bruker: NMR spectrometer, 201808 supply 1GHz NMR spectrometer |
2018-08-06 |
| Univ Warwick–Bruker: NMR spectrometer, 201808 supply Avance 1.0 GHz solid-state NMR spectrometer |
2018-08-06 |
| Arsanis–Gates Foundation: grant, 201808 grant $1.1.m for preclinical development of ASN500 programme |
2018-08-01 |
| Miraca–Qiagen: molecular companion diagnostics, 201808– collab with SRL to introduce of CDx tests in Japan in line with respective drug approvals |
2018-08-01 |
| Bayer–Leo Pharma: investment, 201807–201907 acquisition of global prescription dermatology business of Bayer |
2018-07-31 |
| B&W Tek–Metrohm: investment, 201807 acquisition €na of B&W Tek LLC + several overseas subisidiaries |
2018-07-27 |
| Biocrates–MC Services: public relations, 201807 service existent by MC Services |
2018-07-25 |
| Nabriva–SEVERAL: investment, 201807 public offering $50m net $46.1m with 18.2m ordinary shares at $2.75/share |
2018-07-25 |
| Innovative Medicines Initiative–Agena Bioscience: MassARRAY Technology, 201807– collab use of MassArray system in CANCER-ID Consortium |
2018-07-24 |
| Zavante Therapeutics–Nabriva: investment, 201807 acquisition upfront 8.2m Nabriva ordinary shares (=19.9% shareholding) + $97.5m milestones |
2018-07-24 |
| SHS–SEVERAL: investment, 201807 first closing €90m of SHS V fund with target size of €150m |
2018-07-20 |
| Novartis–MorphoSys: therapeutic antibody, 201807– license excl ww to MOR106 from MOR+GLPG €95m upfront + €850m milestones + royalties + funding |
2018-07-19 |
| Adocia–MC Services: public relations, 201807 service existent PR Europe by MC Services |
2018-07-18 |
| Agilent–AMETEK: FTIR analyzer, 201807 collab developm + manufacturing Miniscan IR LOG FTIR analyzer for in-field oil/grease analysis |
2018-07-18 |
| Beiersdorf–S-Biomedic: skin microbiomics, 201807– collaboration |
2018-07-18 |
| DCPrime–Glycotope: cancer immunotherapy, 201807– license + collab agreement research new approaches to solid tumours |
2018-07-18 |
| S-Biomedic–Beiersdorf: investment, 201807 financing round Series A 1st closing totalling €2m incl lead investor Beiersdorf AG |
2018-07-18 |
| S-Biomedic–JnJ: investment, 201807 financing round Series A 1st closing totalling €2m incl co-investor JnJ Innovation JJDC |
2018-07-18 |
| S-Biomedic–SEVERAL: investment, 201807 financing round Series A 1st closing €2m led by Beiersdorf + incl investiere.ch + JnJ Innovation JJDC |
2018-07-18 |
| S-Biomedic–Verve Capital Partners: investment, 201807 financing round Series A 1st closing totalling €2m incl co-investor investiere.ch |
2018-07-18 |
| B Braun–CeGaT: personalised medicine, 201807 collab establishment of B Braun Precision Medicine Technology (Shanghai) Ltd |
2018-07-17 |
| CeGaT–B Braun: investment, 201807 existent 30% shareholding of B Braun in CeGaT |
2018-07-17 |
| Labfolder–NEC: information technology, 201807– collab €na combining Labfolder s/w with NEC hardware for scalable data storage solutions |
2018-07-17 |
| Polares Medical–Decheng Capital: investment, 201807 financing round totalling $25m incl lead investor Decheng Capital |
2018-07-17 |
| Polares Medical–Earlybird: investment, 201807 financing round totalling $25m incl co-investor Earlybird Venture Capital Berlin |
2018-07-17 |
| Polares Medical–Endeavour Vision: investment, 201807 financing round totalling $25m incl co-investor Endeavour Vision |
2018-07-17 |
| Polares Medical–IDO Investments: investment, 201807 financing round totalling $25m incl co-investor IDO Investments |
2018-07-17 |
| Polares Medical–SEVERAL: investment, 201807 financing round $25m led by Decheng Capital |
2018-07-17 |
| Polares Medical–Wellington Partners: investment, 201807 financing round totalling $25m incl co-investor Wellington Partners |
2018-07-17 |
| Roche–Shionogi: virostatic agent, 201807 license to baloxavir marboxil excl ww without JP + TW to Roche existent |
2018-07-17 |
| Holtzbrinck–Scott Partnership: public relations, 201807– supply service marcom for BioData |
2018-07-16 |
| Genmab–Immatics: cancer immunotherapy, 201807– researc collab + excl license to targets for biospecific I-O drugs $54m upfront + $550m milestones |
2018-07-12 |
| JPK Instruments–Bruker: investment, 201807 acquisition €na of JPK by Bruker |
2018-07-12 |
| Miltenyi Biotec–Scienion: cell handling technology, 201807– collab co-marketing MACSQuant Tyto Cell Sorter with cellenONE X1 Cell Dispenser |
2018-07-12 |
| Forbion–SEVERAL: investment, 201807 first close €270m of Forbion IV fund |
2018-07-11 |
| BioNTech–Consilium: public relations, 201807 service existent international media relations + European IR by CSC |
2018-07-10 |
| BioNTech–Roivant: LNP technology, 201807– license excl to apply Genevant’s LNP delivery technology to 5 of BioNTech’s oncology programs |
2018-07-10 |
| BioNTech–Trophic Communications: public relations, 201807 service existent German media relations by Trophic |
2018-07-10 |
| BioNTech–Westwicke Partners: public relations, 201807 service existent US IR by Westwicke Partners |
2018-07-10 |
| Pionyr Immunotherapeutics–Minapharm: biopharma production, 201807– supply service cell line + process dev + prod of 2nd therap antibody by ProBioGen |
2018-07-10 |
| Roivant–BioNTech: mRNA therapeutics, 201807– collab strategic partnership to develop 5 products for rare disease with Genevant |
2018-07-10 |
| Boehringer–MabVax Therapeutics: antibody cancer drug, 201807 acquisition all rights to preclinical antibody program for solid tumours |
2018-07-09 |
| IMMUNOMONITOR project–Biomax: pharmacogenomics, 201807– collab partner in Eurostars project to develop validation treatm response to cancer vaccines |
2018-07-05 |
| IMMUNOMONITOR project–Enpicom: pharmacogenomics, 201807– collab partner in Eurostars project to develop validation treatm response to cancer vaccines |
2018-07-05 |
| IMMUNOMONITOR project–EU (govt): grant, 201807– Eurostars grant €2m to develop clin validation for treatm response to cancer vaccines |
2018-07-05 |
| IMMUNOMONITOR project–OSE Immunotherapeutics: pharmacogenomics, 201807– collab project partner develop validation treatm response cancer vaccines |
2018-07-05 |
| IMMUNOMONITOR project–Ultimovacs: pharmacogenomics, 201807– collab partner in Eurostars project to develop validation treatm response cancer vaccines |
2018-07-05 |
| IMMUNOMONITOR project–Univ Hamburg: pharmacogenomics, 201807– collab partner Eurostars in project develop validation treatm response cancer vaccines |
2018-07-05 |
| Basilea–Coulter Partners: recruitment services, 201807 supply service placement of Gerrit Hauck as new CTO of Basilea Pharmaceutica Intl Ltd |
2018-07-04 |
| Lactotronic–Bruker: investment, 201807 acquisition €na of Lactotronic BV by Bruker |
2018-07-03 |
| Inveox–SEVERAL: investment, 201807c 2nd financing round €5m from four founding business angels |
2018-07-01 |
| Novartis–France (govt): cell therapy contract manufacturing, 201807– supply production CAR-T cell therapies incl Kymriah by CellforCure |
2018-07-01 |
| NBE Therapeutics–Novo Group: investment, 201806 financing round Series B CHF20m extension by Novo Holdings bringing total Series B to CHF40m |
2018-06-28 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo-2019.png){kind=logo}
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 650x65px](/banner/iito-20181119-650-065-lse-life-sciences-europe-com.jpg)
1 2 3 ... 8 9 10 ... 53 54 55 
Date![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x65px](/banner/iito-20181119-650-065-lsus-life-sciences-usa-com.jpg)
![Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px](/banner/iito-20190621-650-089-life-sciences-asia.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
